tenofovir disoproxil fumarate and emtricitabine

DRUG3 trials

Sponsors

Laboratorio Elea Phoenix S.A., Asociación Civil Impacta Salud y Educación, Peru, Centre for the AIDS Programme of Research in Sauth Africa

Conditions

Acquired Immunodeficiency SyndromeHIV PreventionHIV/AIDS

Phase 1

Bioequivalence Study of Two Formulations With the Association of Tenofovir 300 mg and Emtricitabine 200 mg.

CompletedNCT02583464

Laboratorio Elea Phoenix S.A.Acquired Immunodeficiency Syndrome

Start: 2014-09-30End: 2014-12-31Updated: 2015-10-22

CAPRISA 018 TAF Implant Trial

Active, not recruitingPACTR201809520959443

Centre for the AIDS Programme of Research in Sauth AfricaHIV/AIDS

Start: 2020-02-27Target: 550Updated: 2026-09-14

Unknown Phase

Demonstration Project on the Feasibility to Implement PrEP in MSM and TG Women

Asociación Civil Impacta Salud y Educación, PeruHIV Prevention

Start: 2017-01-23End: 2022-01-31Target: 1000Updated: 2019-07-08

Related Papers

Safety, tolerability, and pharmacokinetics of an annual tenofovir alafenamide silicone subdermal implant in South African women: a two-part, randomised, placebo-controlled, double-blind, first-in-human, phase 1 trial.

2025-06-271 citations

CAPRISA 018: a phase I/II clinical trial study protocol to assess the safety, acceptability, tolerability and pharmacokinetics of a sustained-release tenofovir alafenamide subdermal implant for HIV prevention in women

BMJ Open2022-01-0134 citations